Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$80.7 million.

  • Abeona Therapeutics' Net Cash Flow fell 33128.88% to -$80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 50975.12%. This contributed to the annual value of $8.9 million for FY2024, which is 337031.25% up from last year.
  • Abeona Therapeutics' Net Cash Flow amounted to -$80.7 million in Q3 2025, which was down 33128.88% from $147.6 million recorded in Q2 2025.
  • Abeona Therapeutics' Net Cash Flow's 5-year high stood at $147.6 million during Q2 2025, with a 5-year trough of -$80.7 million in Q3 2025.
  • Moreover, its 5-year median value for Net Cash Flow was $1.5 million (2023), whereas its average is $3.9 million.
  • Over the last 5 years, Abeona Therapeutics' Net Cash Flow had its largest YoY gain of 99177.99% in 2024, and its largest YoY loss of 113595.51% in 2024.
  • Over the past 5 years, Abeona Therapeutics' Net Cash Flow (Quarter) stood at -$5.9 million in 2021, then soared by 158.78% to $3.5 million in 2022, then surged by 180.17% to $9.8 million in 2023, then decreased by 21.82% to $7.6 million in 2024, then plummeted by 1156.89% to -$80.7 million in 2025.
  • Its last three reported values are -$80.7 million in Q3 2025, $147.6 million for Q2 2025, and -$7.4 million during Q1 2025.